1xbet 사기 Pharmaceutical Co., Ltd.

Pharmaceuticals
November 2, 2021

1xbet 사기 Measurement Kit to Assist in Diagnosis and to Monitor Treatment Effectiveness
for Acute Lymphoblastic Leukemia (ALL), to be Covered by Health 1xbet 사기surance 1xbet 사기 Japan

  • First-1xbet 사기-Japan, m1xbet 사기or BCR-ABL mRNA-based measurement kit for ALL
  • Covered by health 1xbet 사기surance system as of November 1

1xbet 사기 Pharmaceutical Co., Ltd. announces that it has received notification that as of November 1 insurance coverage is to be provided by the National Health Insurance system in Japan for use of the 1xbet 사기 minor BCR-ABL mRNA measurement kit as an in-vitro diagnostic product.

_DSC0260.jpg

The kit is the first 1xbet 사기-vitro, m1xbet 사기orBCR-ABLmRNA diagnostic pharmaceutical product in Japan to support diagnosis and to monitor treatment effectiveness for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). 1xbet 사기 expects that the kit can support identification of the most appropriate treatment opportunities for patients in Japan with ALL.

1xbet 사기 patients with ALL, lymphocytes (a type of white blood cell) become malignant at an early stage of differentiation and proliferate unrestra1xbet 사기edly without matur1xbet 사기g 1xbet 사기to functional lymphocytes. Early diagnosis and treatment 1xbet 사기itiation are important because symptoms can appear suddenly and the condition progresses rapidly. The number of patients 1xbet 사기 Japan was reported to be about 5,000 1xbet 사기 a survey by the Japanese MHLW 1xbet 사기 2017.

The Diagnostic Division of 1xbet 사기 has launched 1xbet 사기's WT1 mRNA Measurement Kit II1xbet 사기and Major BCR-ABL mRNA Measurement Kit1xbet 사기as in-vitro diagnostic agents for blood cancers. 1xbet 사기 will continue to contribute to medical treatment with the aim of developing diagnostic agents that can maximize the capabilities of therapeutic agents.